Loading…
TMO
Thermo Fisher Scientific Inc
NYSE· Healthcare· Diagnostics & Research· CUSIP 883556102
$676.54-2.52%Price as of Oct 23, 00:41 UTC · updated once a day, after the close
At a glance
Thermo Fisher Scientific Inc (TMO) is listed on NYSE and classified in Diagnostics & Research, part of the Healthcare sector. It is headquartered in Waltham, United States and has 125,000 employees. The company is worth $250.15B and trades at 35.7x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $44.56B in fiscal 2025, up 3.9% from the year before. Net income was $6.7B. The share price is 4.1% below its 52-week high of $705.79. It pays a dividend yielding 0.28%, and has raised its annual dividend for 8 years in a row in our records. 12 of the 38 superinvestors we track held it at the end of Q3 2026. The largest position belongs to Andreas Halvorsen (Viking Global Investors), at $971.34M. In that quarter, 7 of them opened or added to the position and 4 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Analysis
Articles on this site that cover Thermo Fisher Scientific Inc.
Key metrics
- Market cap
- $250.15B
- P/E
- 35.7x
- Forward P/E
- 24.4x
- P/B
- 4.6x
- Dividend yield
- 0.28%
- Payout
- 9.92%
- EPS
- $18.96
- ROE
- 13.38%
- Profit margin
- 14.94%
- Revenue growth
- +9.10%
- Beta
- —
- 52-week high
- $705.79
- 52-week low
- $435.27
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
- Andreas HalvorsenAddedViking Global Investors · Q2 2026$971.34M1.94M shares · 2.8% of portfolio
- Daniel SundheimAddedD1 Capital Partners · Q2 2026$409.67M817.12K shares · 1.2% of portfolio
- Baillie GiffordReducedBaillie Gifford & Co · Q2 2026$323.7M645.65K shares · 0.3% of portfolio
Ken GriffinReducedCitadel Advisors · Q2 2026$288.28M574.99K shares · 0.2% of portfolio- Steve CohenReducedPoint72 Asset Management · Q2 2026$139.25M277.74K shares · 0.2% of portfolio
- John ArmitageNew positionEgerton Capital · Q3 2026$133.81M198.23K shares · 1.4% of portfolio
- Cliff AsnessAddedAQR Capital Management · Q2 2026$128.99M257.91K shares · 0.0% of portfolio
- Israel EnglanderAddedMillennium Management · Q2 2026$82.96M165.48K shares · 0.1% of portfolio
- Tom GaynerAddedMarkel Group · Q2 2026$36.65M73.1K shares · 0.3% of portfolio
- Stanley DruckenmillerNew positionDuquesne Family Office · Q2 2026$9.63M19.2K shares · 0.2% of portfolio
- Two SigmaReducedTwo Sigma Investments · Q2 2026$8.53M17.01K shares · 0.0% of portfolio
Ray DalioHeldBridgewater Associates · Q2 2026$6.49M12.95K shares · 0.0% of portfolio
Price over time
▲ +9.0% over 5Y.
today you would have $1,105.61▲ +10.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 19 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $579.45 | $520.23 | $530.79 | $550.69 | $667.24 | $465.78 | $324.87 | $223.79 | $189.88 | $141.10 | $141.85 | $125.29 | $111.35 | $63.78 | $44.97 | $55.36 | $47.69 | $34.07 | $57.68 | |
| P/E | 30.9x | 32.7x | 31.5x | 34.4x | 31.2x | 34.3x | 29.2x | 35.4x | 30.9x | 34.0x | 27.7x | 28.8x | 26.6x | 32.0x | 19.9x | 13.0x | 21.9x | 23.7x | 15.1x | 34.1x |
| P/S | 3.3x | 4.8x | 4.6x | 4.7x | 4.7x | 6.7x | 5.7x | 5.1x | 3.7x | 3.6x | 3.0x | 3.3x | 2.9x | 3.3x | 1.8x | 1.4x | 2.1x | 2.0x | 1.4x | 2.6x |
| P/B | 2.6x | 4.0x | 4.0x | 4.3x | 4.8x | 6.4x | 5.3x | 4.4x | 3.2x | 3.0x | 2.6x | 2.6x | 2.4x | 2.6x | 1.5x | 1.1x | 1.4x | 1.3x | 1.0x | 1.8x |
| EPS | $17.74 | $16.53 | $15.45 | $17.63 | $19.46 | $15.96 | $9.17 | $7.24 | $5.59 | $5.09 | $4.92 | $4.71 | $3.48 | $3.21 | $3.46 | $2.53 | $2.01 | $2.25 | $1.69 | |
| Dividend yield | 0.30% | 0.30% | 0.30% | 0.26% | 0.22% | 0.16% | 0.19% | 0.23% | 0.30% | 0.32% | 0.43% | 0.42% | 0.48% | 0.54% | 0.85% | — | — | — | — | — |
| Payout | 9.57% | 9.70% | 9.44% | 9.06% | 6.81% | 5.34% | 5.51% | 8.29% | 9.39% | 10.73% | 11.79% | 12.20% | 12.74% | 17.24% | 16.82% | — | — | — | — | — |
| Profit margin | 11.51% | 15.05% | 14.77% | 13.99% | 15.50% | 19.71% | 19.79% | 14.48% | 12.06% | 10.64% | 11.06% | 11.64% | 11.22% | 9.73% | 9.42% | 11.51% | 9.96% | 8.58% | 9.34% | 7.68% |
| ROE | 9.25% | 12.55% | 12.78% | 12.83% | 15.83% | 18.94% | 18.48% | 12.46% | 10.65% | 8.76% | 9.39% | 9.25% | 9.22% | 7.55% | 7.62% | 8.84% | 6.74% | 5.51% | 6.57% | 5.17% |
Median of the years shown; P/E years above 200x are left out.
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
$251.29
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
$460.45
Median P/E of 24.3 among peers in the sector.
Earnings
$586.06
Median P/E of 30.9 across this company’s own years on record.
Cash flow
$146.59
Cash flow growing 2.1% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
$254.09
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
Dividends
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
How the average is calculated
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
Earnings $432.60 (avg. of 3)+Cash flow $146.59+Operating $254.09÷ 3 =$277.76
$277.76
5 methods answered, across 3 families.
$208.32
Room for errors in the reported numbers.
$676.54
-58.9% from the average.
Models, not forecasts, and not investment advice. How each formula works →
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| AMGNAmgen Inc | $447.28 | 27.2x | 20.7x | 2.25% | 91.47% | $241.81B |
| AZNAstrazeneca PLC | $172.57 | 25.8x | 5.3x | 1.85% | 21.96% | $267.64B |
| NVSNovartis AG | $156.27 | 23.6x | 7.1x | 3.03% | 30.35% | $297.02B |
| GILDGilead Sciences Inc | $157.19 | — | 16.5x | 2.09% | -20.68% | $194.91B |
| ABTAbbott Laboratories | $102.51 | 37.4x | 3.4x | 2.46% | — | $177.38B |
| NVONovo Nordisk A S | $39.43 | 9.6x | 5.3x | 4.57% | 59.81% | $174.01B |
About the company
- 125,000
- Waltham, United States